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CASE REPORT
acute and persistent improvements in oxygen saturation, so-
matic growth, exercise capacity, and reduction in anticoagulant 
requirements.(8-10) There are no commercially available devices 
that are designed specifically for Fontan fenestration occlusion, 
except for the PFO Star device described by Boshoff, et al.(5) 
The most commonly used device is the Amplatzer® Septal 
Occluder (ASO; St Jude Medical, St Marks, MN).(7,11,12) We 
report a case of successful closure of Fontan fenestration using 
an Occlutech patent ductus arteriosus (PDA) closure device 
(Occlutech®, Helsingborg, Sweden). 
CASE PRESENTATION 
We present a 21-year-old male patient, who presented with 
dysmorphism and severe cyanosis at birth. He was diagnosed 
with William-Beuren syndrome, congenital tricuspid atresia, 
and pulmonary atresia with a secundum atrial septal defect 
(ASD). The patient had bilateral modified Blalock-Taussig 
shunts, as he had hypoplastic branch pulmonary arteries. He 
had a bidirectional Glenn Shunt at 11 years of age, and a TCPC 
with a Fontan circuit-to-right atrium fenestration done when 
aged 19 years. A year later, the patient presented with easy 
fatigability, exercise intolerance, and severe cyanosis with 
INTRODUCTION
William-Beuren syndrome is due to a microdeletion in the 
chromosome region 7q11.23, and commonly presents with 
progressive supravalvular aortic stenosis and non-progressive 
or improving pulmonary artery stenosis.(1) It is unusual for this 
syndrome to present with a single ventricle (univentricular) 
congenital cardiac aberration. Management of a univentricular 
heart traditionally involves staged shunting – including a Blalock-
Taussig Shunt, a Glenn Shunt (with a Blalock-Taussig Shunt 
take-down), and completion of a total cavo-pulmonary con-
nection (TCPC, “Fontan circuit”) with or without a right atrium-
to-TCPC fenestration. The introduction of fenestration at the 
time of completion of the “Fontan circuit”, was a significant 
advance in the peri-operative care of patients with univentri-
cular physiology. In the immediate post-operative period, the 
ability to shunt blood from right to left through the fenestra-
tion reduces volume and pressure load on the pulmonary 
circulation and augments systemic cardiac output – thereby 
reducing morbidity and mortality, while awaiting the cardio-
vascular system’s adaptation to the new haemodynamic situa-
tion.(2-4) However, in the long-term, the fenestration is a source 
of continuing systemic desaturation, and a potential conduit 
for paradoxical thrombo-embolisation.(5,6) Device closure of a 
Fontan fenestration is a widely accepted strategy to eliminate 
these potential complications.(7) It is safe and associated with 
ABSTRACT
We present a case of Fontan fenestration closure using 
an Occlutech patent ductus arteriosus occluder. The 
patient was diagnosed with tricuspid atresia, pul-
monary atresia and secundum ASD at birth. He had a 
bilateral modifi ed Blalock-Taussig shunt to promote 
growth of hypoplastic branch pulmonary arteries. He 
had a bidirectional Glenn Shunt at 11 years of age, and 
a total cavo-pulmonary connection (TCPC) with a 
fenestration at 19 years of age. He presented a year 
later with severe exercise intolerance and cyanosis. 
Cardiac catheterisation showed hypoxemia, normal 
pulmonary pressures, patent Fontan circuit and 
branch pulmonary arteries, and a Fontan circuit-to-
right atrium fenestration with right to left shunting. 
A short shank Occlutech PDA occluder with a waist 
of 8mm, a pulmonary end of 10mm, an aortic disk 
of 16mm, and a length of 7mm, was selected to close 
the fenestration through the transvenous approach. 
The fenestration achieved complete immediate occlu-
sion with this device.  SAHeart 2018;15:210-212
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oxygen saturation of 84% in room air. The echocardiogram 
showed a patent TCPC with a fenestration shunting right 
to left. There was also a high haemoglobin concentration of 
16.7g/dl, and low arterial blood gas oxygen saturation of 89%.
Under general anaesthesia, both venous and arterial access 
were achieved. Hypoxemia was confirmed in that the systemic 
arterial saturations remained at 89%, with systemic venous 
saturations very low at 54%. The pulmonary artery pressures 
were normal, with a mean pressure of 13mmHg, and there was 
no indication of obstruction in the branch pulmonary arteries. 
The inferior vena cava venogram confirmed that the TCPC 
was patent with a fenestration that was shunting from right 
to left, and measuring 4.6mm in diameter. The superior vena 
cava venogram confirmed a patent Glenn Shunt and branch 
pulmonary arteries (Figure 1A). Based on the size of the 
defect and as per the manufacturer’s guidelines (Occlutech®, 
Helsingborg, Sweden), an Occlutech® PDA occluder with a 
waist of 8mm and pulmonary end of 10mm, was selected to 
close the fenestration (Figure 1B). This is a short shank (with 
a short length) device that will endothelialise in 6 months, 
and will not cause turbulence in this low-pressure system. 
Another reason why this device was chosen, is that it is much 
cheaper compared to the commonly used ASO (Occlutech®, 
Helsingborg, Sweden; St Jude Medical, St Marks, MN). We used 
the device itself for test occlusion, instead of a balloon inter-
rogation. We did an angiogram before releasing the device 
from the delivery wire. When we were satisfied that the device 
had closed the defect completely, the device was released. The 
fenestration was successfully closed, with no residual shunting 
across it (Figure 1C). Following fenestration closure, the sys-
temic arterial saturations improved immediately from 89% - 
100% in room air. The patient showed clinical improvement 
following fenestration closure, in that he was asymptomatic and 
remained with oxygen saturation of more than 95% in room air 
on follow-up. 
DISCUSSION
Device closure of a Fontan fenestration is a widely adopted 
procedure. It is safe and associated with immediate and 
sustained overall clinical improvement and reduced needs for 
anticoagulation.(8-10) The Amplatzer® septal occluder has been 
used for a long time to occlude Fontan fenestrations – most 
probably due to its longstanding availability and because the 
fenestration might be considered to be a neo-atrial septal 
defect.(7,11) The Amplatzer® duct occluder type 2 has also 
been used with success.(11,12) The device seems well suited for 
Fontan fenestration closure, as it is a soft, flexible device that 
can conform to a variety of fenestration lengths and angles, and 
the discs are known to flatten with time, enabling them to 
follow the contour of the GORE-TEX conduit in the total 
cavo-pulmonary circulation. It is also a low profile device, with 
most device sizes deliverable through concomitant low-profile 
delivery sheaths (4Fr and 5Fr delivery systems).(12) The new 
Occlutech® paravalvular leak device (Occlutech®, Helsingborg, 
Sweden) has been used for the closure of Fontan fenestra-
tion.(13)  This device offers a combination of a small delivery 
sheath size, high flexibility, less material, and a low profile. 
The Occlutech® duct occluder (Occlutech®, Helsingbong, 
Sweden) has a meshwork of self-expandable nickel and titanium 
(nitinol) alloy wire. It has a “champagne cork” configuration. 
FIGURE 1: Leafl et involvement versus successful repair.
A.  Fontan circuit conduit angiogram showing patent conduit and conduit-to-right atrium fenestration measuring 4.6mm.
B. Occlutech duct occluder deployment in the fenestration.
C.  Complete fenestration occlusion with Occlutech duct occluder in situ.  
B: 4.6mm
CF: 0.2884mm/p (x1.5)
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There is a flat disk on the aortic side, which is continuous with 
the body (‘’shank’’) of the device through nitinol braiding. The 
aortic side of the shank measures 3.5mm - 14mm in diameter 
and “flares up” at the pulmonic end – thus giving it a diameter 
1.5mm - 4mm larger than the aortic end of the shank 
(Figure 1B). The device length varies from 4.25mm - 16mm. 
Embedded in the body are polyethylene terephthalate (PET) 
threads that are expected to enhance defect closure rate. 
These devices are delivered through 6F to 9F Cook’s delivery 
system, depending on device size. This is the first case report, 
to the best of our knowledge, of the use of a Occlutech®  PDA 
occluder for Fontan circuit fenestration occlusion. 
CONCLUSION
A Fontan circuit-to-right atrium fenestration has become 
standard peri-operative management of single-ventricle heart 
conditions undergoing total cavo-pulmonary circulation pallia-
tion. Percutaneous closure of the fenestration with various 
devices has also become standard management. Percutaneous 
closure of this defect with an Occlutech® PDA occluder, 
expands the armamentarium of devices that can be used for 
closure of this defect. The device is much more cost-effective 
compared to other devices used for this purpose.
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